Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Hanmi And Merck in Discussion to Sell Hanmi's Hypertension Drug In Other Countries including Six Asia-Pacific Countries

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Hanmi Pharmaceutical and MSD are pushing to sell Hanmi's incrementally modified hypertensive amlodipine product Amosartan in other countries includng six Asia-Pacific countries under Merck's brand Cozzar XQ

You may also be interested in...



Will GSK-Hanmi Deal Trigger Similar Tie-ups With Korean Pharmas?

Korea’s Hanmi Pharmaceutical is positioning itself as a partner of choice for reformulations and fixed-dose combinations after inking its second major deal with a multinational.

Will GSK-Hanmi Deal Trigger Similar Tie-ups With Korean Pharmas?

Korea’s Hanmi Pharmaceutical is positioning itself as a partner of choice for reformulations and fixed-dose combinations after inking its second major deal with a multinational.

Merck And Korea's Hanmi Build On Cozaar Deal From One Country To More Than 30, And More Could Be On The Way

SEOUL - Merck & Co. Inc.'s emphasis on lifecycle management for its Cozaar brand is good news for Hanmi Pharmaceutical, as Merck recently expanded a marketing rights deal for Hanmi's ARB/CCB combination that pairs amlodipine with Merck's losartan. A deal that started in 2009 for the Korean market now stands at 30 markets and signs point to an even broader deal in the future

Related Content

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel